PVLA

Palvella is a clinical-stage dermatology/rare-disease company (formed via the December 2024 reverse merger of Legacy Palvella into Pieris) whose entire value rests on unapproved candidates — QTORIN rapamycin (lead, microcystic LM) and QTORIN pitavastatin. The 10-K is explicit: it has 'incurred significant operating losses since inception,' expects to 'continue to incur significant operating losses for the foreseeable future,' and expects R&D to 'increase substantially.' That is already visible in the numbers — R&D jumped +180% to $22.8M, the net loss widened to -$41.7M, operating cash flow was -$25.0M, and ROE is -149%. There is no recurring product revenue; the $42.8M/$18.7M FY2023 figures are legacy/pre-merger and not representative of the operating company, which makes the headline 51.8x P/S meaningless rather than reassuring.

The balance sheet is thin for the burn ahead: $58.0M cash against a -$25.0M operating burn that management itself says will rise means roughly two years of runway before a raise — and dilution has already started, with shares up +29.9% year-over-year. Stockholders' equity is just $28.0M against a -$135M accumulated deficit. Against that, the market is assigning a $2.22B market cap, i.e. ~38x cash, valuing the company almost entirely on the option value of late-stage trial readouts and regulatory approvals that have not happened.